Patents by Inventor Genevieve Desjardins

Genevieve Desjardins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETERODIMERIC Fc VARIANTS SELECTIVE FOR Fc GAMMA RIIB
    Publication number: 20240294646
    Abstract: Heterodimeric Fc variants comprising one or more asymmetric amino acid mutations in the CH2 domain and having increased selectivity of binding to Fc?RIIb as compared to a parental Fc region, polypeptides comprising the heterodimeric Fc variants and polynucleotides encoding the heterodimeric Fc variants. The one or more asymmetric mutations comprise replacement of a loop in the CH2 domain, a mutation at position 236 in the CH2 domain, or a combination of replacement of a loop in the CH2 domain and a mutation at position 236 in the CH2 domain.
    Type: Application
    Filed: May 20, 2021
    Publication date: September 5, 2024
    Inventors: ERIC ESCOBAR-CABRERA, Gregory LAKATOS, Leonard G. PRESTA, Genevieve DESJARDINS, Abhishek MUKHOPADHYAY, Antonios SAMIOTAKIS, Surjit DIXIT, Jian (James) ZHANG, James MCWHIRTER, Gavin JONES
  • IMMUNOGLOBULIN Fc REGION VARIANTS COMPRISING STABILITY-ENHANCING MUTATIONS
    Publication number: 20230303715
    Abstract: Fc variants are described comprising one or more amino acid mutations that increase the stability of the Fc variant as compared to a parental Fc that does not include the one or more amino acid mutations, as well as polypeptides comprising an Fc variant and polynucleotides encoding an Fc variant.
    Type: Application
    Filed: May 20, 2021
    Publication date: September 28, 2023
    Inventors: Genevieve DESJARDINS, Eric ESCOBAR-CABRERA, Antonios SAMIOTAKIS, Gavin Carl JONES
  • MASKED IL12 FUSION PROTEINS AND METHODS OF USE THEREOF
    Publication number: 20230122079
    Abstract: The present disclosure relates to masked IL12 fusion proteins, compositions comprising the same and methods of using the compositions for the treatment of a variety of diseases including cancer.
    Type: Application
    Filed: March 23, 2021
    Publication date: April 20, 2023
    Inventors: Ryan Blackler, Gesa Volkers, David Douda, Thomas Spreter Von Kreudenstein, Genevieve Desjardins, Nicole Afacan
  • ANTI-PD-1/LAG3 BISPECIFIC ANTIBODIES
    Publication number: 20210371530
    Abstract: Provided herein are anti-PD-1/LAG3 bispecific antibodies and antigen-binding fragments. Also provided here are methods and uses of these antibodies and antigen-binding fragments in the treatment of cancer or infectious disease.
    Type: Application
    Filed: July 23, 2021
    Publication date: December 2, 2021
    Inventors: Laurence FAYADAT-DILMAN, Veronica JUAN, Shireen KHAN, Shaopeng HUANG, Hua YING, Eric Escobar CABRERA, Genevieve DESJARDINS
  • ANTI-PD-1/LAG3 BISPECIFIC ANTIBODIES
    Publication number: 20210363256
    Abstract: Provided herein are anti-PD-1/LAG3 bispecific antibodies and antigen-binding fragments. Also provided here are methods and uses of these antibodies and antigen-binding fragments in the treatment of cancer or infectious disease.
    Type: Application
    Filed: July 23, 2021
    Publication date: November 25, 2021
    Inventors: Laurence FAYADAT-DILMAN, Veronica JUAN, Shireen KHAN, Shaopeng HUANG, Hua YING, Eric Escobar CABRERA, Genevieve DESJARDINS
  • Anti-PD-1/LAG3 bispecific antibodies
    Patent number: 11072658
    Abstract: Provided herein are anti-PD-1/LAG3 bispecific antibodies and antigen-binding fragments. Also provided here are methods and uses of these antibodies and antigen-binding fragments in the treatment of cancer or infectious disease.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: July 27, 2021
    Assignees: MERCK SHARP & DOHME CORP., ZYMEWORKS, INC.
    Inventors: Laurence Fayadat-Dilman, Veronica Juan, Shireen Khan, Shaopeng Huang, Hua Ying, Eric Escobar Cabrera, Genevieve Desjardins
  • ANTI-PD-1/LAG3 BISPECIFIC ANTIBODIES
    Publication number: 20190233518
    Abstract: Provided herein are anti-PD-1/LAG3 bispecific antibodies and antigen-binding fragments. Also provided here are methods and uses of these antibodies and antigen-binding fragments in the treatment of cancer or infectious disease.
    Type: Application
    Filed: January 31, 2019
    Publication date: August 1, 2019
    Inventors: Laurence Fayadat-Dilman, Veronica Juan, Shireen Khan, Shaopeng Huang, Hua Ying, Eric Escobar Cabrera, Genevieve Desjardins